FDA Continues to Defend Zohydro Approval, State Prosecutors Criticize

Washington Drug Letter
A A
As more critics of the FDA’s approval of the painkiller Zohydro ER come forward, the agency says it will not limit approval of new opioid painkillers to those with abuse-deterrent properties.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00